

Predictive significance and diagnostic accuracy of plasma fibrinogen levels for coronary stenting outcomes

Tarun Bansal¹, Anand Shukla², Rujuta Parikh², Gaurav Singh^{2*}, Ashish Mishra¹, Lalan Singh³, Krutika Patel⁴, Iva Patel⁴, Utsav Patel²

¹Apollo Hospital, Lucknow, Gujarat India

²Department of cardiology, U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Asarwa, Ahmedabad-380016, Gujarat, India

³Department of cardiology, Shyam Shah Medical College, Rewa-486001, Rewa, India

⁴Department of cardiology, U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad-380016, Gujarat, India

Abstract

Objective: The advancement in percutaneous transluminal coronary angioplasty (PTCA) has led to it becoming the predominant mode of revascularization. Post PTCA adverse events in the form of stent thrombosis, recurrent ischemia, unplanned revascularization, recurrent hospitalization etc. result in morbidity as well as mortality. Biomarkers predicting such outcomes can be useful in initiating more aggressive medical therapy and greater modification of risk factors. This study was undertaken to study the predictive significance of periprocedural plasma fibrinogen levels for coronary stenting outcomes.

Methods: 80 patients diagnosed as either chronic stable angina (CSA), unstable angina (UA), Non ST Elevation Myocardial Infarction (NSTEMI) or late presentation ST Elevation Myocardial Infarction (STEMI) undergoing planned PTCA were included in study. Patients were evaluated for clinical history, electrocardiogram (ECG), two dimensional echocardiography (2D-echo) and cardiac biomarkers (Creatinine Phosphokinase-MB isomer (CK-MB) and Troponin I). Serum fibrinogen level was measured 24 hours prior to PTCA along with routine pre-operative investigations; and also 24 hours after coronary stenting. Patients were followed for six months. Outcome measure was taken to be freedom from cardiac related adverse events, including rehospitalisation, unplanned repeat revascularization, definite stent thrombosis, transient ischemic attack, stroke and all-cause mortality.

Results: Fibrinogen level ≥ 393 mg/dL, 24 hours prior to percutaneous transluminal coronary angioplasty, was associated with higher major adverse cardiac and cerebrovascular events (MACCE) rates (60%) as compared to those with fibrinogen level < 393 mg/dL (3.6%). Fibrinogen level ≥ 427 mg/dL 24 hours after percutaneous transluminal coronary angioplasty, was associated with higher major adverse cardiac and cerebrovascular events rates (65%) as compared to those with fibrinogen level < 427 mg/dL (6.7%).

Conclusion: The current study demonstrates that higher baseline and post procedural fibrinogen, is an independent predictor of 6 months major adverse cardiac and cerebrovascular events after elective percutaneous coronary intervention.

Key words: Coronary stent outcomes, major adverse cardiac and cerebrovascular events, plasma fibrinogen, stent diameter

(Heart Vessels Transplant 2022; 6: 10.24969/hvt.2022.365)

Abbreviations:

2D-echo	Two-Dimensional Echocardiography	MACCE	Major Adverse Cardiac and Cerebrovascular Events
CAD	Coronary Artery Disease	NSTEMI	Non-ST-Elevation Myocardial Infarction
CPKMB	Creatinine Phosphokinase-MB isomer	PCI	Percutaneous coronary intervention
CRP	C-reactive protein	PTCA	Percutaneous Transluminal Coronary Angioplasty
CSA	Chronic Stable Angina	ROC	Receiver operating characteristic curve
FDP	Fibrinogen degradation products	STEMI	ST - Elevation Myocardial Infarction
Gp IIb/IIIa	Glycoprotein IIb/IIIa receptor	Trop-I	Troponin I
ICAM-1	Interaction with Intracellular Adhesion Molecule-1		
ISR	In-Stent Restenosis		
LVEF	Left Ventricular Ejection Fraction		

Address for Correspondence: Gaurav Singh, Department of Cardiology, UNMICRC, Civil Hospital Campus, Asarwa, Ahmedabad-380016, Gujarat, India M: +91 757 395 25 10, Fax: +91 792 268 20 92

Email: mdmedgaurav@gmail.com

Received: 04.10.2022 **Revised:** 26.11.2022 **Accepted:** 28.11.2022

Introduction

Traditionally, percutaneous coronary intervention (PCI) has become a common treatment of coronary artery disease (CAD). Early recoil, alteration in blood vessels, release of vasoactive and thrombogenic factors and neo-intimal proliferation have been suggested as significant contributors to the restenosis after coronary angioplasty (1, 2).

Plasma fibrinogen is an acute phase reactant with known inflammatory mechanism, but it also affects platelet aggregation and blood viscosity (3, 4). Inflammation leads to development of neo-intimal hyperplasia which results in restenosis of the stented vessels. Many inflammatory molecules have been studied as potential indicators of CAD risk.

These include the cytokines (tumor necrosis factor – alpha (TNF-alpha), interleukin (IL)-1-beta, IL-10 and IL-6), endothelial activation markers (E-selectin and vascular cell adhesion molecule (VCAM)-1), circulating adhesion proteins etc. These are produced in liver and increase or decrease in response to inflammatory stimuli (5). Serum fibrinogen, serum amyloid A, and high sensitivity C-reactive protein (hs-CRP) are among the acute-phase proteins that increase during inflammation and have been studied as predictors of CAD. Certain markers like adiponectin and IL-10 are downregulated in inflammation (6).

Fibrinogen levels have correlated positively with number of diseased vessels as well as the severity of CAD. In addition, in patients with chronic stable angina (CSA) without any known coronary risk factors, fibrinogen was the strongest predictor of global coronary score, number and severity of coronary artery stenosis (7).

Although epidemiological studies have evaluated role of fibrinogen in CAD, there are still aspects that need further investigation.

Hence, this study was undertaken to evaluate predictive significance and diagnostic accuracy of fibrinogen in stent outcomes in patients who underwent elective PTCA for acute coronary syndrome (ACS) or CSA.

Methods

Study design:

This is a prospective observational study of 80 consecutive patients fulfilling the inclusion and exclusion criteria. It was conducted between November 2016 and January 2019 at a tertiary cardiac care hospital in Ahmedabad, Gujarat, India.

Participants:

Inclusion criteria:

- All patients with CSA who underwent elective PCI.
- All patients with ACS including UA and NSTEMI who underwent elective PCI.
- All patients with hemodynamically stable ST elevation myocardial infarction (STEMI) who were late presenters (out of window period) and underwent PCI minimum 72 hours after presentation.
- All patients who gave written informed consent.

CSA was defined as episodes of typical anginal pain of more than 2 months duration (8). ACS refers to spectrum of clinical syndrome compatible with acute myocardial ischemia and includes unstable angina, NSTEMI and STEMI. Unstable angina (UA) was defined as rest angina lasting more than 20 minutes or new onset angina in less than 2 months or crescendo angina increasing in frequency, duration or intensity of symptoms. NSTEMI was defined as evidence of myocardial ischemia and myocardial necrosis in the form of positive cardiac biomarkers (9).

Exclusion Criteria:

- Patients with STEMI of less than 72 hours on presentation
- Patients who were late presenters of STEMI but had any indication for rescue PTCA like arrhythmia or hemodynamic instability.
- Patients with NSTEMI needing urgent revascularization.
- Patients with any active infection.
- Patients with use of intravenous glycoprotein IIb/IIIa inhibitor prior to or during the PCI.
- Patients with extensive CAD requiring more than two stents deployment, chronic total occlusion (CTO) lesion; or use of special hardware like rotablation.

The history of relevant coronary risk factors including hypertension, diabetes mellitus, smoking and family history was recorded. Electrocardiogram (ECG), 2D echocardiography and cardiac biomarkers (CK-MB and Troponin I) were also recorded.

Fibrinogen measurement

Plasma fibrinogen levels were analyzed by automated hematology analyser STA-compact MAX reagent kit. Normal plasma fibrinogen levels range from 150 to 450 mg/dl. Two ml of venous blood sample was collected in 3.2% sodium citrate added tubes from the patients 24 hours prior to and 24 hours after the coronary stenting for the analyses of plasma fibrinogen levels in mg/dl.

Percutaneous coronary intervention

Coronary stenting was done either using radial or femoral route under a local anesthetic agent. All patients underwent PTCA with the use of a second-generation drug eluting stent (DES). The stent size was assessed angiographically and depended on the discretion of the interventional cardiologist. Patency of the vessel was assessed by coronary angiography after the procedure was completed. Thrombolysis in myocardial infarction (TIMI) 3 flow was achieved in all. All patients who underwent PTCA received loading dose of tablet clopidogrel 300 mg and tablet aspirin 300 mg prior to the procedure. Intravenous heparin was given during the procedure. Intravenous or intracoronary glycoprotein IIb/IIIa inhibitor was not used. Post PTCA patient received tablet aspirin 150mg, second antiplatelet drug (either clopidogrel, prasugrel or ticagrelor at the discretion of treating cardiologist) and statin for minimum of six months.

Follow up and outcomes

Patients were followed up for six months with regular OPD visits. Outcome measure was taken to be freedom from cardiac related adverse events at six months. Cardiac related events included major adverse cardiac and cerebrovascular events (MACCE) –re-hospitalization for a suspected ACS, unplanned repeat revascularization, definite or probable stent thrombosis, transient ischemic attack, ischemic or hemorrhagic stroke, or any death. Occurrences of adverse events were collected from the admitted patient's case records and active surveillance by telephonic conversations.

Statistical analysis

All statistical analyses were performed using SPSS v 22.0 software (Chicago, IL, USA). Continuous variables were summarized as mean (standard deviation),

whereas categorical variables were expressed as percentage of the sample. Continuous variables were compared using the unpaired student's t-test and categorical using Chi-square test. Receiver operating characteristic curve (ROC) analysis was used to find the cut-off value of fibrinogen in our study population. Binary logistic regression analysis was used to find follow up outcome association with risk factors. Group differences associated with a p value ≤ 0.05 were considered statistically significant.

Results

Baseline demographic characteristics:

In the study population, mean age was 54.62 (10.94) years with 80% male patients and 20% female patients. Overall 33.8% of patients had diabetes mellitus, 65% had hypertension and 21.3% were smokers; 55% of the patients had CSA, 45% had ACS as mentioned in Table 1. The mean left ventricular ejection fraction (LVEF) of the study population was 48.04 (8.97)%. Maximum patients had NYHA class-II (50%) followed by NYHA Class-I, III and IV (33.75%, 13.75% and 2.5%) respectively. Mean baseline fibrinogen levels 24 hours prior to PCI was 358.33 (107.09) mg/dl and after stenting mean fibrinogen level was 381.55 (94.62) mg/dl. Other cardiac biomarkers like troponin I (6.95 (6.15) ng/L) and CK-MB (55.49 (91.25) U/L) was also measured. Of all cohort, 76.3% patients were treated with one stent and 23.8% were treated with two stents. The highest number of patients had occlusion of left anterior descending artery (LAD) (68.8%), followed by left circumflex artery (LCx) (33.8%) and right coronary artery (RCA) (28.7%).

Follow up characteristics

At six months follow up, 17 (21.2%) patients had MACCE out of which 15 were male and 2 were female patients. The presenting event was not found to be significantly associated with MACCE ($p=0.54$). Occurrence of MACCE events was not significantly associated with presence of risk factors, clinical parameters, biochemical parameters and procedural parameters as detailed in Table 2. Occurrence of MACCE event was associated with periprocedural fibrinogen level ($p<0.0001$) and stent diameter ($p=0.004$).

Table 1. Baseline characteristics	
Variables	N=80(%)
Age, years	54.63 (10.94)
Male, n(%)	64(80)
Female, n(%)	16(20)
Diabetes mellitus type 2, n(%)	27(33.8)
Hypertension, n(%)	52(65)
Smoking, n(%)	17(21.3)
LAD stenosis, n(%)	55(68.8)
LCx stenosis, n(%)	27(33.8)
RCA stenosis, n(%)	23(28.7)
No. of patients with single- vessel disease, n(%)	62 (77.5)
No. of patients with double-vessel disease, n(%)	11 (13.75)
No. of patients with triple - vessel disease, n(%)	7 (8.75)
Electrocardiogram on presentation	
Sinus rhythm, n(%)	80 (100)
QRS duration (ms) , n(%)	92.3 (6.5)
ST elevation with Q waves, n(%)	9 (11.3)
ST depression, n(%)	31 (38.75)
T wave inversion, n(%)	24 (30)
Coronary artery disease types	
ACS-NSTEMI, n(%)	8(10)
ACS-UA, n(%)	7(8.8)
Stable angina, n(%)	44(55)
STEMI, n(%)	21(26.2)
Occurrence of MACCE , n(%)	17(21.3)
NYHA class, n(%)	
Class-I	27(33.75)
Class-II	40(50)
Class-III	11(13.75)
Class-IV	2(2.5)
Biochemical parameters	
Hemoglobin, gr/dl	12.87 (1.5)
Serum creatinine, mg/dl	0.85 (0.17)
Troponin I ng/L	6.95 (16.15)
CK-MB U/L	55.49 (91.25)
Serum fibrinogen (mg/dl) 24 hrs prior stenting	358.33 (107.09)
Serum fibrinogen (mg/dl) 24hrs after stenting	381.55 (94.62)
LVEF, %	48.04 (8.97)
Patients with one stent, n(%)	61(76.3)
Patients with two stents, n(%)	19(23.8)
Stent length, mm	29.90 (7.2)
Stent diameter, mm	2.92 (0.36)
ACS- Acute coronary syndrome, CK-MB- creatine kinase-myoglobin binding, LAD- left anterior descending artery, LCx- left circumflex artery, LVEF-left ventricular ejection fraction, NSTEMI- non ST-elevation myocardial infraction; MACCE- major adverse cardiac and cerebrovascular events, RCA- right coronary artery; STEMI- ST-elevation	

Table 2. Six- month follow- up outcomes with and without major adverse cardiac and cerebrovascular events

Variables	MACCE (n= 17)	No MACCE (n=63)	p
Age, years	56.18 (8.82)	54.21 (11.48)	0.51
Male, n(%)	15(88.2)	49(77.8)	0.54
Female, n(%)	2(11.8)	14(22.2)	
Diabetes mellitus type 2, n(%)	8(41.1)	19(30.2)	0.31
Hypertension, n(%)	11(64.7)	41(65.1)	0.98
Smoking, n(%)	5(29.4)	12(19)	0.36
Baseline fibrinogen 24 hours prior stenting \geq 393 mg/dL, n(%)	15(88.2)	10(15.9)	<0.0001
Fibrinogen 24hrs after stenting \geq 427mg/dL, n(%)	13(76.5)	7(11.1)	<0.0001
Coronary artery disease type, n(%)			
ACS-NSTEMI	4(23.5)	4(6.3)	0.1
ACS-UA	1(23.5)	6(9.5)	0.99
Chronic stable angina	6(35.3)	38(60.3)	0.12
STEMI	6(35.3)	15(23.8)	0.52
Biochemical parameters			
Hemoglobin, gr/dl	12.19 (1.26)	13.05 (1.26)	0.03
Serum creatinine, mg/dl	0.86 (0.16)	0.85 (0.16)	0.87
Troponin I, ng/L	9.9 (16.04)	6.05 (16.04)	0.4
CK-MB, U/L	77.82 (96.04)	48.95 (89.60)	0.25
Procedural parameters, n(%)			
LAD	15(88.2)	40(63.5)	0.10
LCX	5(29.4)	22(34.9)	0.89
RCA	5(29.4)	18(28.6)	0.82
Stent 1	12(70.6)	49(77.8)	0.77
Stent 2	5(29.4)	14(22.2)	
Stent diameter \leq 2.75	13(76.5)	21(33.3)	0.004
Stent diameter $>$ 2.75	4(23.5)	42(66.7)	0.05

MACCE- major adverse cardiac and cerebrovascular events, ACS- acute coronary syndrome; NSTEMI- non ST-elevation myocardial infraction, UA- unstable angina; STEMI- ST-elevation myocardial infraction, LVEF- left ventricular ejection fraction, CK-MB- creatine kinase-myoglobin binding, LAD- left anterior descending artery, LCx- left circumflex artery, RCA- right coronary artery

Predictors of MACCE

In patients who had MACCE, mean fibrinogen level 24 hours prior to PTCA was 485.52 (103.14) mg/dl. Receiver operating characteristic curve (ROC) analysis showed that fibrinogen level at cut off $>$ 393 mg/dl, 24 hours prior to PCI, was associated with higher MACCE rates with 0.91 area under curve (AUC); 88.2% sensitivity and specificity 85.7(95% CI 0.82 to 0.96; $p < 0.0001$) (Fig.1). In patients who had MACCE, mean fibrinogen level 24 hours after PTCA was 487.53 (103.58) mg/dl 24 hours after the PCI. ROC analysis showed that fibrinogen level at cut off $>$ 427 mg/dl 24

hours after PCI, was associated with higher MACCE rates with 0.85 AUC; 76.5% sensitivity and specificity 90.5% (95% CI 0.75 to 0.92; $p < 0.0001$) (Fig.2).

On comparative analysis, significantly more patients with baseline serum fibrinogen more than 393 mg/dL experienced rehospitalization for UA ($p < 0.0001$), unplanned revascularization ($p = 0.003$) and stent thrombosis ($p = 0.003$) as compared to patients with serum fibrinogen less than 393 mg/dL 24 hours before PTCA (Table 3). Similar results were seen when comparing patients with fibrinogen levels less than and more than 427 mg/dL, 24 hours post stenting.

Table 3. Major adverse cardiac and cerebrovascular events according to fibrinogen level before and after stenting

Variables	24 hours before stenting		p	24 hours after stenting		p
	<393 mg/dl (n=55)	≥393 mg/dl (n=25)		<427 mg/dl (n=60)	≥427 mg/dl (n=20)	
Rehospitalization for UA, n(%)	1(1.8%)	9(36%)	<0.0001	3(5%)	7(35%)	0.002
Rehospitalization for NSTEMI, n(%)	0	1(4%)	0.68	0	1(5%)	0.56
Re-vascularization, n(%)	0	5(20%)	0.003	0	5(25%)	0.0005
Stent thrombosis, n(%)	0	5(20%)	0.003	0	5(25%)	0.0005
TIA/ Ischemic Stroke/ Hemorrhagic stroke, n(%)	1(1.8%)	0	0.68	1(1.7%)	0	0.56
Death n(%)	0	0	-	0	0	-

NSTEMI- non ST-elevation myocardial infraction, TIA- transient ischemic attack, UA-unstable angina

FIBRINOGEN (MG/DL) (150-450) 24 HRS PRIOR STENTING




Figure 1. Receiver operating characteristic curve (ROC) of fibrinogen level 24 hours prior to percutaneous coronary intervention associated with MACCE shows 0.91 AUC (95% CI 0.82 to 0.96; p<0.0001) with 88.2% sensitivity and specificity of 85.7%

FIBRINOGEN (MG/DL) (150-450) 24 HRS AFTER STENTING




Figure 2. Receiver operating characteristic curve (ROC) of 24 hours fibrinogen level post percutaneous coronary intervention associated with MACCE shows 0.85 AUC (95% CI 0.75 to 0.92; p<0.0001) with 76.5% sensitivity and specificity of 90.5%

Distribution of risk factors like DM-II (p=0.43), hypertension (p=0.53) and smoking (p=0.22) was not associated with fibrinogen level. Fibrinogen level was associated with presenting event. There were more patients in ≥393 mg/dl group (24%), who presented

with NSTEMI as compared to <393 mg/dL group (3.6%) (p=0.02). Also, patients with CSA had lower level of serum fibrinogen levels (p=0.01). Biomarkers like troponin I and CK-MB were also elevated in ≥393

Table 4. Distribution of risk factors, presenting events and biochemical parameters according to levels of fibrinogen before and after stenting

Variables	24 hours before stenting		p	24 hours after stenting		p
	<393 mg/dl (n=55)	≥393 mg/dl (n=25)		<427 mg/dl (n=60)	≥427 mg/dl (n=20)	
Male, n(%)	42(76.4)	22(88)	0.37	45(75)	19(95)	0.05
Female, n(%)	13(23.6)	3(12)		15(25)	1(5)	
Diabetes mellitus type 2, n(%)	17(30.9)	10(40)	0.43	18(30)	9(45)	0.22
Hypertension, n(%)	37(67.3)	15(60)	0.53	40(66.7)	12(60)	0.59
Smoking, n(%)	10(18.2)	7(28)	0.22	12(20)	5(25)	0.98
Coronary artery disease types, n(%)						
ACS-NSTEMI	2(3.6)	6(24)	0.02	4(6.7)	4(20)	0.2
ACS-UA	6(10.9)	1(4)	0.56	7(11.7)	0	0.25
Stable angina	36(65.5)	8(32)	0.01	37(61.7)	7(35)	0.07
STEMI	11(20)	10(40)	0.11	12(20)	9(45)	0.06
MACCE	2(3.6)	15(60)	<0.0001	4(6.7)	13(65)	<0.0001
Biochemical parameters						
Hemoglobin, mg/dl	13.08 (1.16)	12.41 (2.01)	0.06	13.18 (1.34)	11.93 (1.6)	0.001
Creatinine, mg/dl	12.41 (2.01)	0.82 (0.19)	0.2	0.84 (0.15)	0.9 (0.21)	0.18
Troponin I, ng/L	3.69 (13.00)	13.19(19.74)	0.02	5.12 (14.25)	11.78 (19.97)	0.12
CK-MB, U/L	38.42 (72.84)	89.6(114.09)	0.02	49.65(90.77)	71.55(92.96)	0.36
ACS- acute coronary syndrome, CK-MB- creatine kinase-myoglobin binding, NSTEMI- non ST-elevation myocardial infarction, UA- unstable angina, STEMI- ST-elevation myocardial infarction,						

Occurrence of MACCE was significantly associated with fibrinogen level 24 hours before stenting and 24 hours after stenting (p<0.0001). Overall, 60% patients with fibrinogen level >393 mg/dL 24 hours prior to PTCA developed MACCE as compared to 3.6% of patients with fibrinogen level <393 mg/dL. Similarly, 65% of patients with fibrinogen level >427 mg/dL 24 hours after PTCA developed MACCE, as compared to 6.7% of patients with fibrinogen level <427 mg/dL (Table 4).

In patients who had MACCE, mean stent diameter was 2.69 (0.38) mm and mean stent length was 32.0 (5.83) mm. ROC analysis showed that coronary stent diameter with a cut off 2.75 mm was associated with higher MACCE rates with AUC 0.75; sensitivity of 76.5% and specificity of 66.7% (95% CI 0.64 to 0.84; p=0.001). 23.5% of patients with coronary stent diameter >2.75mm was associated with MACCE, as compared to 76.5% of patients with stent diameter ≤2.75 mm.

Binary logistic regression was used to find out the predictors of MACCE (Table 5). Regression analysis for baseline fibrinogen level showed odds ratio 1.68 (95% CI 0.82-3.44; p=0.15), and 1.24 for fibrinogen level 24 hours post PTCA (95% CI 0.59-2.58; p=0.57). Stent diameter ≤ 2.75 mm had odds ratio 5.02 (95% CI 2.50-10.05; p<0.0001). According to multiple regression analysis higher fibrinogen level was seen in patients suffering from MACCE but association for same could not be established and requires further investigation. However, stent diameter independently predicts MACCE.

Discussion

The current study demonstrates that higher level of periprocedural plasma fibrinogen is seen more in patients with MACCE after elective PTCA. Also, use of small calibre stents was associated with higher MACCE, but neither the stent length nor the presenting event for PTCA was associated with MACCE.

Table 5. Regression analysis for the predictors of MACCE			
Variables	Odds ratio	95% CI lower-upper	p
Serum fibrinogen 24 hours prior stenting	1.68	0.82 to 3.44	0.15
Serum fibrinogen 24 hours after stenting	1.24	0.59 to 2.58	0.57
Stent diameter	5.02	2.50 to 10.05	<0.0001
MACCE - major adverse cardiac and cerebrovascular events			

Fibrinogen as predictor of MACCE

Similar to us, Kavitha et al. (10) reported the mean baseline plasma fibrinogen levels to be higher in patients who developed repeat angina and myocardial infarction post stenting. Also, serial measurements of fibrinogen levels remained higher in patients with adverse events ($p=0.003$) (10).

In a study by Otsuka et al. (11), patients with pre-procedural fibrinogen level >345 mg/dL had greater occurrence of cardiac death, target vessel myocardial infarction and target lesion revascularization after undergoing PTCA. They concluded that higher pre-procedural fibrinogen level was an independent predictor of coronary stent outcome (11). Another study by Mahmud et al. (12) showed that baseline fibrinogen value greater than 360.2 (135.5) mg/dL was associated with higher MACCE after PCI in the form of periprocedural myocardial infarction, re-hospitalization for ACS, urgent revascularization, stroke and death (12). The Dual Antiplatelet Therapy (DAPT) study also identified multiple factors predicting late ischemic events including the use of smaller-diameter stents, similar to the current study (13). Studies by Germing et al and Rahel et al, also suggested increased levels of fibrinogen to be associated with adverse cardiac events after intracoronary stenting (14, 15) Song et al. (16) also reported higher fibrinogen level to predict death or nonfatal re-infarction in patients who underwent PCI (16). Long term outcome of fibrinogen was also assessed in a study by Yuan et al. (17). Elevated fibrinogen levels were associated with all-cause mortality and cardiac mortality at median follow up of 5.1 years. It is possible that a higher fibrinogen threshold predicts ischemic risk during PTCA due to administration of potent antiplatelet and anticoagulant therapy, while a lower threshold might be associated with longer-term MACCE.

Proposed mechanism of fibrinogen role in atherosclerosis

Fibrinogen has several effects in the event of atherosclerosis. It can infiltrate into the arterial wall and bind low-density cholesterol and other clotting factors. Fibrinogen degradation products (FDP) stimulate smooth muscle cell proliferation in tunica media and loading of cholesterol in macrophages. It elevates plasma viscosity due to higher molecular weight and asymmetry. Fibrinogen binds to red cells and stimulates red cell accumulation further increasing plasma viscosity. Fibrinogen increases adhesion of leukocytes and platelets to coronary plaques by interaction with ICAM-1 on leukocytes and endothelial cells. It increases platelet aggregation by binding to platelet Gp IIb/IIIa. It also increases platelet reactivity. It also participates in later stages of coagulation cascade leading to thrombosis (3, 4).

A better understanding of other fibrinogen characteristics such as concentration variation with age or clinical presentation, variation in isoforms, intracellular storage and release and binding characteristics may further refine the relations between an elevated fibrinogen level and MACCE after PTCA.

Stent characteristics predicting MACCE

Plitt et al. found stent diameter less than 2.5 mm to be associated with higher events of target vessel revascularization and myocardial infarction at 1 year follow up (18). Small vessel diameter of reference vessel <2.5 mm is usually associated with female gender, diabetes mellitus, calcification and more extensive CAD. Hence, stenting of such lesions is associated with lower success rates (19). A study by Xu et al. (20) also suggested that "bigger was better" and stent diameters more than 2.5 mm were associated with lesser target vessel revascularizations.

Study limitations

Only incidence of adverse events during six-month follow-up was assessed. Longer outcomes need to be assessed. Angiographic follow-up was not done and hence percentage of restenosis was not determined. Post-PCI dual antiplatelet therapy and thienopyridine selection was determined at time of discharge after index procedure and may have been subsequently modified.

Conclusion

The current study demonstrates that baseline fibrinogen, post procedural fibrinogen and stent diameter are independent predictors of 6-month major adverse cardiac and cerebrovascular events after elective percutaneous coronary intervention.

Ethics: Informed consent was obtained from all individual participants

The study has been approved by the institutional ethics committee (UNMICRC/CARDIO/2016/14).

Peer-review: External and internal

Conflict of interest: None to declare

Authorship: T.B., A.Sh., R. P., G.S., A.M., L.S., K.P., I.P., U.P. equally contributed to preparation of manuscript and fulfilled authorship criteria.

Acknowledgement and funding: This work was supported by U. N. Mehta Institute of Cardiology and Research Centre itself and received no specific grant from any funding agency, commercial or not for profit sectors.

References

1. Rajagopal V, Rockson SG. Coronary restenosis: a review of mechanisms and management. *Am J Med* 2003; 115: 547–53.
2. Samsuzzaman SM, Khaled MF, Ahmed SM, Al Amin M, Rashed R, Abedin MZ, et al. Periprocedural plasma fibrinogen level and clinical outcome of coronary stent implantation. *Univ Heart J* 2021; 17: 122-7.
3. Smith EB, Keen GA, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. *Arterioscler Off J Am Heart Assoc* 1990; 10: 263–75.
4. Stefanadi E, Tousoulis D, Papageorgiou N, Briasoulis A, Stefanadis C. Inflammatory biomarkers predicting events in atherosclerosis. *Curr Med Chem* 2010; 17: 1690–707.
5. Tracy RP. Emerging relationships of inflammation, cardiovascular disease and chronic diseases of aging. *Int J Obes* 2003; 27(S3): S29–34.
6. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-

analyses of prospective studies. *JAMA* 1998; 279: 1477.

7. Ahmed M, Chowdhury NA, Sofdar G, Rahman Z, Majumder AAS. Fibrinogen and coronary artery disease – a review. *Univ Heart J* 2013; 9: 40-6.

8. Rousan TA, Thadani U. stable angina medical therapy management guidelines: a critical review of guidelines from the European Society of Cardiology and National Institute for Health and Care Excellence. *Eur Cardiol Rev* 2019; 14: 18–22.

9. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, Part I. *Mayo Clin Proc* 2009; 84: 917–38.

10. Kavitha S, Sridhar MG, Satheesh S. Periprocedural plasma fibrinogen levels and coronary stent outcome. *Indian Heart J*; 2015; 67: 440-3.

11. Otsuka M, Hayashi Y, Ueda H, Imazu M, Kohno N. Predictive value of preprocedural fibrinogen concerning coronary stenting. *Atherosclerosis* 2002; 164: 371–8.

12. Mahmud E, Behnamfar O, Lin F, Reeves R, Patel M, Ang L. Elevated serum fibrinogen is associated with 12-month major adverse cardiovascular events following percutaneous coronary intervention. *J Am Coll Cardiol* 2016; 67:2556-7.

13. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SLT, Gershlick AH, Cohen DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. *JAMA* 2016; 315: 1735.

14. Germing A, von Dryander S, Machraoui A, Bojara W, Lawo T, Grewe P, et al. Hyperfibrinogenemia increases the risk of cardiac events after coronary artery stenting. *Heart Vessels* 2000; 15: 263–7.

15. Rahel BM, Visseren FL, Suttrop MJ, Plokker TH, Kelder JC, de Jongh BM, et al. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. *Cardiovasc Res* 2003; 60: 136-40.

16. Song J, Yu T, Sun Z, Li Z, He D, Sun Z. Comparison of prognostic significance between serum fibrinogen and Global Registry of Acute Coronary Events score for prognosis of patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention. *Coron Artery Dis* 2020; 31: 124-9.

17. Yuan D, Jiang P, Zhu P, Jia S, Zhang C, Liu Y, et al. Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study. *Cardiovasc. Diabetol* 2021; 20: 1-3.

18.Plitt A, Claessen BE, Sartori S, Baber U, Chandrasekhar J, Aquino M, et al. Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: results from a large single-center registry. *Catheter Cardiovasc Interv* 2020; 96: 558–64.

19.Schunkert H, Harrell L, Palacios IF. Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization. *J Am Coll Cardiol* 1999; 34: 40–8.

20.Xu T, Feng B, Zheng Z, Li L, Zeng W, Wang D, et al. Association of stent diameter and target vessel revascularization in patients undergoing percutaneous coronary intervention: a secondary retrospective analysis based on a Chinese cohort study. *BMC Cardiovasc Disord* 2021; 21: 402.